(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
9 June 2011 (09.06.2011)

PCT

(10) International Publication Number
WO 2011/067616 A1

(51) International Patent Classification:
A61K 39/40 (2006.01) *C07K 16/12* (2006.01)

(21) International Application Number:
PCT/GB2010/052035

(22) International Filing Date:
6 December 2010 (06.12.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0921288.7 4 December 2009 (04.12.2009) GB
PCT/GB2010/050288
19 February 2010 (19.02.2010) GB

(71) Applicants *(for all designated States except US)*: **HEALTH PROTECTION AGENCY** [GB/GB]; Porton Down, Salisbury Wiltshire SP4 0JG (GB). **MICROPHARM LIMITED** [GB/GB]; Station Road Industrial Estate, Newcastle Emlyn Carmarthenshire SA38 9BX (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **SHONE, Clifford** [GB/GB]; Health Protection Agency, Porton Down, Salisbury wiltshire SP4 0JG (GB). **ROBERTS, April** [GB/GB]; Health Protection Agency, Porton Down, Salisbury Wiltshire SP4 0JG (GB). **LANDON, John** [GB/GB]; MicroPharm Limited, Station Road Industrial Estate, Newcastle Emlyn Carmarthenshire SA38 9BX (GB).

(74) Agent: **MACLEAN, Martin**; Mathys & Squire LLP, 120 Holborn, London Greater London EC1N 2SQ (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

(54) **Title**: THERAPIES FOR PREVENTING OR SUPPRESSING CLOSTRIDIUM DIFFICILE INFECTION

Figure 2



(57) **Abstract**: The present invention provides an antibody composition comprising ovine antibodies, for use in the prevention or treatment of *C. difficile* infection wherein the antibodies bind to a *C. difficile* toxin, and wherein said prevention or treatment is by oral delivery of the antibody composition. Also provided is a pharmaceutical composition of ovine antibodies for oral delivery, which further comprises one or more means for protecting the antibodies from trypsin and/ or chymotrypsin and/ or stomach acid.

WO 2011/067616 A1